Abstract: The present invention concerns combinations of inecalcitol with an anti-CD38 agent such as daratumumab, MOR 202 or isatuximab for the treatment of cancer, such as hematological malignancies by increasing or inducing the expression of CD-38 by inecalcitol.
Type:
Grant
Filed:
July 20, 2017
Date of Patent:
November 19, 2019
Assignee:
HYBRIGENICS S.A.
Inventors:
Susan Benjamin, Cécile Planquette, Rémi Delansorne
Abstract: The present invention relates to quinazolin-4-one compounds of formula (I?), their process of preparation and uses thereof. These compounds are useful as selective and reversible inhibitors of ubiquitin specific proteases, particularly USP7, for treating e.g. cancer, neurodegenerative diseases, inflammatory disorders and viral infections.
Abstract: The present invention is concerned with a method and a kit for detecting an interaction between a first membrane bound test protein or fragment thereof and a second test protein or fragment thereof which is either membrane bound or soluble with an in vivo genetic system based in yeast, bacterial or mammalian cells. The system makes use of the reconstitution of the split ubiquitin protein.
Type:
Grant
Filed:
March 28, 2003
Date of Patent:
September 6, 2016
Assignee:
Hybrigenics Services S.A.S.
Inventors:
Igor Stagljar, Michael Hottiger, Daniel Auerbach
Abstract: The present invention concerns the discovery of new selective inhibitors of ubiquitin specific proteases, their process of preparation and their therapeutic use.
Abstract: The present invention provides new formulations of 14-epi-analogues of vitamin D, such as inecalcitol, providing improved absorption profile.
Abstract: The present invention concerns a process of isomerizing trans fused bicyclic derivatives into cis fused bicyclic derivatives and the preparation of vitamin D or analogs thereof comprising said isomerization step.
Type:
Grant
Filed:
January 24, 2011
Date of Patent:
April 19, 2016
Assignee:
HYBRIGENICS SA
Inventors:
Jean-Luc Moutou, Florent Mouton, Gilles Pellegrino, Jean Lafay
Abstract: The present invention relates to quinazolin-4-one compounds of formula (I?), their process of preparation and uses thereof. These compounds are useful as selective and reversible inhibitors of ubiquitin specific proteases, particularly USP7, for treating e.g. cancer, neurodegenerative diseases, inflammatory disorders and viral infections.
Abstract: The present invention thus concerns a method for treating and/or preventing rickets, osteoporosis, osteomalacia, psoriasis, autoimmune diseases such as multiple sclerosis or type I diabetes, hyperparathyroidism, benign prostate hyperplasia, any type of cancer or any vitamin D relevant disease comprising administering inecalcitol at doses comprised between 1 mg/day and 100 mg/day to a human patient in need thereof.
Abstract: The present invention concerns the discovery of new selective inhibitors of ubiquitin specific proteases, their process of preparation and their therapeutic use.
Abstract: The present invention provides new formulations of 14-epi-analogues of vitamin D, such as inecalcitol, providing improved absorption profile.
Abstract: The present invention provides new formulations of 14-epi-analogues of vitamin D, such as inecalcitol, providing improved absorption profile.
Abstract: Use of a polypeptide selected from the group consisting of USP13, USP26, USP38, USP42 or USP46 as a screening tool for an agent for treating cancer.
Type:
Application
Filed:
October 29, 2009
Publication date:
September 29, 2011
Applicants:
Les Laboratoires Servier, Hybrigenics
Inventors:
Olivier Geneste, John Hickman, Frédéric Colland, Laurent Daviet
Abstract: The invention relates to a method of screening and identifying modulators of the protein interaction between new peptides and anti-apoptotic members of the Bcl-2 protein family. The modulators identified on the basis of this method are administered to patients with cancer in order to bring about apoptotic-type and/or autophagic-type programmed cell death in those patients.
Type:
Grant
Filed:
January 31, 2006
Date of Patent:
April 19, 2011
Assignees:
Les Laboratories Servier, Hybrigenics
Inventors:
Olivier Geneste, John Hickman, Jean-Christophe Rain
Abstract: The present invention concerns new compounds of formula (I), their process of preparation and their therapeutic use wherein R3, R4, R5, R6, Y, Het1, T, U, V, W, X, Ru, Rv and Rw are as defined in claim 1.
Abstract: The invention lies within the field of seeking out and identifying new peptides which interact with anti-apoptotic members of the Bcl-2 protein family, by means of the two-hybrid system. The invention relates to a method of screening and identifying modulators of the protein interaction between those new peptides and anti-apoptotic members of the Bcl-2 protein family. The modulators identified on the basis of this method are administered to patients with cancer in order to bring about apoptotic-type and/or autophagic-type programmed cell death in those patients.
Type:
Application
Filed:
January 31, 2006
Publication date:
December 31, 2009
Applicants:
Les Laboratoires Servier, Hybrigenics
Inventors:
Olivier Geneste, John Hickman, Jean-Christophe Rain
Abstract: The present invention relates to protein-protein interactions involved in AIDS. More specifically, the present invention relates to complexes of polypeptides or polynucleotides encoding the polypeptides, fragments of the polypeptides, antibodies to the complexes, selected Interacting Domains (SID®) which are identified due to the protein-protein interactions, methods for screening drugs of agents which modulate the interaction of proteins and pharmaceutical compositions that are capable of modulating the protein-protein interactions.
Type:
Application
Filed:
May 26, 2004
Publication date:
February 16, 2006
Applicant:
Hybrigenics
Inventors:
Pierre Legrain, Jean-Christophe Rain, Richard Benarous, Stephane Emiliani, Clarissa Berlioz-torrent, Guillaume Blot
Abstract: The present invention relates to nucleic acids encoding SID® polypeptides which bind selectively to a polypeptide encoded by a pathogenic strain of the hepatitis C virus, as well as to the SID® polypeptides which are encoded by said nucleic acids. The invention also concerns vectors comprising a nucleic acid encoding a SID® polypeptide as well as host cells transformed with such vectors. The invention is also directed to two-hybrid methods which make use of the nucleic acids encoding a SID® polypeptide selected from a pathogenic strain of the hepatitis C virus as well as to methods for selecting molecules which inhibit the binding between a SID® polypeptide and a polypeptide which specifically binds thereto.
Type:
Grant
Filed:
August 2, 2001
Date of Patent:
December 20, 2005
Assignee:
Hybrigenics
Inventors:
Pierre Legrain, Simon Whiteside, Jerome Wojcik
Abstract: The present invention concerns collections of recombinant cell clones derived from a prokaryotic genome, more particularly from Helicobacter pylori genome, useable for two-hybrid systems and methods to produce such collections. The invention further relates to then identification of H. pylori protein-protein interactions and to the application of said collections of recombinant cell clones and said identified proteins interactions to the pharmaceutical and diagnostic field.
Type:
Grant
Filed:
October 30, 2001
Date of Patent:
July 12, 2005
Assignee:
Hybrigenics S.A.
Inventors:
Pierre Legrain, Luc Selig, Jean-Christophe Rain